The intermediate target of $140 may be low. Even though AGPH & its supporters are making extensive claims about Viracept, in my discussions with various consumer product firms, I have discovered that they, in addition to Roche may be interested in a buyout of AGPH. This is due to the unique properties of product. Besides knocking down viral burden in HIV+ patients (proved by Dr. Amy Patrick) until the next return of Hale-Bopp, Viracept is quite useful for other applications that have greater economic potential than its use for HIV. For example, my dog Wolfie has dandruff. After dissolving Viracept in the appropriate solvent, I add the mixture to his bath. For the next 10 days, his coat is free of tangles, shiny, and btw - EVEN FREE OF FLEAS! Second: Even though I have regular maid service, I still have a bit of mildew in my shower stall. Even Formula 409 won't remove it, but Viracept works in a jiffy. Because its chemical activity is so robust, after the maid has used it in the shower stall, whatever is left is used as a car polish. The rain beads off my car weeks after the initial application. So, even though there are disagreements regarding Viracept's use as a protease inhibitor, we should feel safe in knowing the applications of Viracept that are not included in the share price. You will be reading more on this in the coming weeks from a highly regarded analyst in New York.
LONG AND LOVING IT - |
